In the Regroup trial focusing on coronary artery bypass grafting (CABG), 28.6% developed postoperative atrial fibrillation (POAF). Among 269 POAF patients, 85 received oral anticoagulation (OAC) with warfarin, and 184 did not. During active follow-up, stroke rates were similar (3.5% OAC vs. 5.4% no-OAC), but major adverse cardiac events were higher with OAC (20% vs. 11.4%). Longer follow-up revealed increased all-cause mortality in the OAC group (20% vs. 11.4%). The study suggests a need to reassess the risk-benefit ratio of OAC in post-CABG POAF patients.
Journal Article by Almassi GH, Quin JA (…) Zenati MA et 5 al. in J Surg Res
Published by Elsevier Inc.